Vetoquinol has been granted EU marketing authorisation for Felpreva (tigolaner/emodepside/praziquantel) for spot-on prevention and treatment of mixed parasitic infestations/infections in cats1.

Felpreva is the first spot-on parasiticide for cats that covers tapeworms in addition to other endoparasites including gastrointestinal roundworms and lungworms, and ectoparasites (fleas, ticks and mites) for up to three months with a single dose.

It is licensed for treatment of cats with, or at risk from, mixed parasitic infestations/infections, including:

  • Endoparasites
  • Gastrointestinal roundworms: infection with Toxocara cati, Toxascaris leonina and Ancylostoma tubaeforme
  • Lungworms: infection with Aelurostrongylus abstrusus and Troglostrongylus brevior
  • Tapeworms: infection with Dipylidium caninum and Taenia taeniaeformis
  • Ectoparasites: Flea (Ctenocephalides felis), tick (Ixodes ricinus, Ixodes holocyclus) and mite (Otodectes cynotis) infestations, as well as mild to moderate cases of notoedric mange (caused by Notoedres cati). It can also form part of a treatment strategy for flea allergic dermatitis.

Matthieu Frechin, Vetoquinol CEO, said: “Marketing authorisation is a pivotal achievement for both Vetoquinol and Felpreva.

"It is a breakthrough treatment with convenience and simplicity of use combined with long-lasting efficacy.

"We believe that Felpreva will be a real game changer for this area of veterinary medicine, demonstrating our commitment to the parasiticide market.” 

It is anticipated that Felpreva will be available in Europe early in 2022.

Reference

  1. European Commission Union Register of Veterinary Medicinal Products – Felpreva. 2021. Available from: https://ec.europa.eu/health/documents/community-register/html/v277.htm [Accessed 16 November 2021].